These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 35014745

  • 1. Prolonged twice-daily administration of oclacitinib for the control of canine atopic dermatitis: a retrospective study of 53 client-owned atopic dogs.
    Denti D, Caldin M, Ventura L, De Lucia M.
    Vet Dermatol; 2022 Apr; 33(2):149-e42. PubMed ID: 35014745
    [Abstract] [Full Text] [Related]

  • 2. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
    Little PR, King VL, Davis KR, Cosgrove SB, Stegemann MR.
    Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
    Carrasco I, Ferrer L, Puigdemont A.
    J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.
    Olivry T, Lokianskiene V, Blanco A, Mestre PD, Bergvall K, Beco L.
    Vet Dermatol; 2023 Apr; 34(2):99-106. PubMed ID: 36330780
    [Abstract] [Full Text] [Related]

  • 14. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis.
    Nishiyama T, Kusakabe M, Imanishi I, Hisano T, Fukamachi T, Taguchi N, Iyori K, Hsiao YH.
    Vet Dermatol; 2023 Dec; 34(6):523-531. PubMed ID: 37485602
    [Abstract] [Full Text] [Related]

  • 15. A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis.
    Qin JJ, Zhu H, Song ZW, Hou XJ, Wang XM, Wang L, Li JX.
    Res Vet Sci; 2024 May; 171():105221. PubMed ID: 38490043
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ear tip ulcerative dermatitis treated with oclacitinib in 25 dogs: a retrospective case series.
    Colombo S, Cornegliani L, Vercelli A, Fondati A.
    Vet Dermatol; 2021 Aug; 32(4):363-e100. PubMed ID: 34250688
    [Abstract] [Full Text] [Related]

  • 20. Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.
    Panteri A, Strehlau G, Helbig R, Prost C, Doucette K.
    Vet Dermatol; 2016 Feb; 27(1):22-e7. PubMed ID: 26660461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.